Literature DB >> 17486069

Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains.

M Sundvall1, L Peri, J A Määttä, D Tvorogov, I Paatero, M Savisalo, O Silvennoinen, Y Yarden, K Elenius.   

Abstract

Cleavable isoforms of the ErbB4 receptor tyrosine kinase release a soluble intracellular domain (ICD) that may translocate to the nucleus and regulate signaling. However, ErbB4 gene is alternatively spliced generating CYT-1 and CYT-2 isoforms with different cytoplasmic tails. Here, we addressed whether the two alternative ErbB4 ICDs of either CYT-1 (ICD1) or CYT-2 (ICD2) type differ in signaling to the nucleus. Confocal microscopy and extraction of nuclear cell fractions indicated that significantly more ICD2 translocated to the nuclei when compared to ICD1. Unlike the membrane-anchored 80 kDa fragments derived from full-length ErbB4 isoforms, the two ICDs did not differ from each other in metabolic stability or ubiquitylation. However, ICD2 was phosphorylated at tyrosine residues to a higher extent and demonstrated greater in vitro kinase activity than ICD1. Mutating the ATP-binding site within ICD2 kinase domain (ICD2 K751R) blocked its tyrosine phosphorylation and significantly reduced its nuclear translocation. When expressed in the context of full-length ErbB4, ICD2 was also more efficient than ICD1 in promoting transcriptional activation of the STAT5 target gene beta-casein. These findings indicate that the two alternative ICDs of ErbB4 differ in their nuclear accumulation, and that the mechanism involves differential kinase activity but not ubiquitin-regulated ICD stability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17486069     DOI: 10.1038/sj.onc.1210501

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  35 in total

1.  Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling.

Authors:  Ilkka Paatero; Anne Jokilammi; Pekka T Heikkinen; Kristiina Iljin; Olli-Pekka Kallioniemi; Frank E Jones; Panu M Jaakkola; Klaus Elenius
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

2.  Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms.

Authors:  Maria Sundvall; Anna Korhonen; Ilkka Paatero; Eugenio Gaudio; Gerry Melino; Carlo M Croce; Rami I Aqeilan; Klaus Elenius
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-11       Impact factor: 11.205

3.  The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.

Authors:  Anjali Naresh; Ann D Thor; Susan M Edgerton; Kathleen C Torkko; Rakesh Kumar; Frank E Jones
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 4.  HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.

Authors:  Frank E Jones
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-13       Impact factor: 2.673

5.  Genome-wide meta-analysis identifies novel loci associated with free triiodothyronine and thyroid-stimulating hormone.

Authors:  M Popović; A Matana; V Torlak; T Boutin; D Brdar; I Gunjača; D Kaličanin; I Kolčić; V Boraska Perica; A Punda; O Polašek; M Barbalić; C Hayward; T Zemunik
Journal:  J Endocrinol Invest       Date:  2019-03-07       Impact factor: 4.256

Review 6.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

Review 7.  Role of ErbB4 in breast cancer.

Authors:  Maria Sundvall; Kristiina Iljin; Sami Kilpinen; Henri Sara; Olli-Pekka Kallioniemi; Klaus Elenius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

8.  Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.

Authors:  Sunitha V Bachawal; Vikram B Wali; Paul W Sylvester
Journal:  BMC Cancer       Date:  2010-03-08       Impact factor: 4.430

9.  Cell death or survival promoted by alternative isoforms of ErbB4.

Authors:  Maria Sundvall; Ville Veikkolainen; Kari Kurppa; Zaidoun Salah; Denis Tvorogov; E Joop van Zoelen; Rami Aqeilan; Klaus Elenius
Journal:  Mol Biol Cell       Date:  2010-10-13       Impact factor: 4.138

10.  Hypoxia-inducible factor-1α induces ErbB4 signaling in the differentiating mammary gland.

Authors:  Ilkka Paatero; Tiffany N Seagroves; Katri Vaparanta; Wen Han; Frank E Jones; Randall S Johnson; Klaus Elenius
Journal:  J Biol Chem       Date:  2014-06-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.